

PharmAust to present at Emerging ASX Gems Conference on Friday 3 November 2023

2 November 2023 – Perth, Australia: PharmAust Limited (ASX: PAA) (Company), a clinical-stage biotechnology company, is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by CEO, Michael Thurn who will present at The Capital Network's Emerging ASX Gems Conference.

Event Emerging ASX Gems
Date Friday 3 November 2023
Time 9am – 11:30am AEDT
Format Webinar

Register The event is free and investors can register online to view the presentation here:
<https://www.eventbrite.com/e/739003237577?aff=oddtcreator>

The event will livestream from 9am – 11:30am AEDT and can be accessed at any time on The Capital Network's YouTube.

This announcement is authorised by the Board.

Enquiries:

Dr Michael Thurn
Chief Executive Officer
investorenquiries@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical studies in humans and Phase 2 clinical studies in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical studies.